Bandingkan metode

	Kriteria Diagnostik Rome IV untuk Sindrom Usus Iritabel	Skala Kualitas Hidup Terkait Kesehatan GERD	Simple Clinical Colitis Activity Index
Bidang	Gastroenterologi	Gastroenterologi	Gastroenterologi
Keluarga	Process / pipeline	Process / pipeline	Process / pipeline
Tahun asal	2016	1996	1998
Pencetus	Rome Foundation (multinational expert consensus)	Velanovich, V., Zhang, Y., Hollis, J. B., et al.	Walmsley, R. S., Ayres, R. C., Pounder, R. E., and Allan, R. N.
Tipe	Diagnostic Criteria	Self-report	Clinician-rated
Sumber perintis	Mearin, F., Lacy, B. E., Chang, L., et al. (2016). Bowel disorders. Gastroenterology. Published online June 2016 by the Rome Foundation.	Velanovich, V., Zhang, Y., Hollis, J. B., Feldman, M. I., Sampliner, R., Guan, W., & Escamilla, C. (1996). Presenting symptoms and outcome measures in reflux esophagitis. Digestive Diseases and Sciences, 41(10), 1865–1873.	Walmsley, R. S., Ayres, R. C., Pounder, R. E., & Allan, R. N. (1998). A simple clinical colitis activity index. Gut, 43(1), 29–32.
Alias	Rome IV IBS, Rome Criteria	GERD-HRQL, GERD-HRQoL	SCCAI
Terkait	4	4	4
Ringkasan	The Rome IV criteria are the internationally accepted diagnostic standard for irritable bowel syndrome (IBS), published in 2016 by the Rome Foundation. These criteria define IBS as recurrent abdominal pain (≥1 day per week for ≥3 months) associated with altered bowel habits, without structural or biochemical abnormalities. IBS is subtyped into four patterns—IBS-constipation predominant (IBS-C), IBS-diarrhea predominant (IBS-D), IBS-mixed (IBS-M), and IBS-unclassified (IBS-U)—based on stool consistency patterns.	The GERD Health-Related Quality of Life Scale (GERD-HRQL) is a concise, validated patient-reported outcome measure for assessing the symptomatic and functional impact of gastroesophageal reflux disease (GERD). Developed by Velanovich and colleagues in 1996, the 9-item GERD-HRQL measures heartburn frequency and severity, regurgitation, and impact on sleep and medication use. The scale is highly responsive to proton pump inhibitor (PPI) therapy and is widely used in GERD trials and clinical practice.	The Simple Clinical Colitis Activity Index (SCCAI) is a practical, bedside tool for assessing disease activity in ulcerative colitis and colonic Crohn's disease. Published in 1998 by Walmsley and colleagues, the SCCAI condenses disease assessment into six items that can be administered in a office visit without laboratory or endoscopic data. It provides rapid, reproducible quantification of disease severity and is ideal for frequent monitoring in routine clinical practice.